Logo | Name | Σ | ||
---|---|---|---|---|
ANSM Agence nationale de sécurité du médicament et des produits de santé [Automatic translation follows] For safe, effective, innovative and accessible health products The National Agency for the Safety of Medicines and Health Products is the public actor that allows, on behalf of the State, access to health products in France and ensures their safety throughout their life cycle. At the heart of the health system, we act in the service of patients and their safety. We promote access to innovative products via authorization procedures adapted to each stage of the life of the drug before and after it is placed on the market. Through our assessments, our expertise and our monitoring … | 158 | 105 | 36 | |
Haute Autorité de Santé [Automatic translation follows] Official page of the High Authority for Health (HAS), an independent public authority with a scientific character The HAS is an independent public authority whose aim is to contribute to the regulation of the health system through quality. Its missions in the fields of the evaluation of health products, professional practices, the organization of care and public health, aim to ensure that all patients and users have sustainable and equitable access to care that is as effective, safe and efficient as possible. | 460 | 340 | 110 | |
Agence Régionale de Santé Grand Est [Automatic translation follows] Acting for the health of all The Regional Health Agency is the contact for health professionals and the medico-social sector, government departments, local authorities, elected officials, management bodies, users and their representatives. It dialogues with all territories and its actions are conducted in compliance with the rights of users and in consultation with health democracy bodies. health care provision, medico-social provision, public health, and health democracy | 193 | 130 | 25 | |
Ministère de la Santé [Automatic translation follows] Official account of the Ministry of Health and Access to Care The Ministry of Health and Access to Care prepares and implements the Government's policy in the areas of public health, prevention and access to care. health, solidarity, public administration, poverty, care, and solidarity | 1251 | 932 | 182 | |
SATT Sud-Est Transforming an invention into an innovation is a wonderful experience. And we’re fortunate, it is our job. From dream to reality, from lab to market | a researcher and his/her team make an extraordinary discovery. But how can an idea be transformed into a solution, and how can an invention be turned into an innovation? This is the start of a race against time to find the partner company capable of upholding that ambition. Fortunately, SATT Sud-Est is there to help in this undertaking and make this great story come true. Transforming an invention into an innovation is a wonderful … Tags: SATT Network Sectors: National and local authorities Research | 278 | 81 | 104 | |
Leem [Automatic translation follows] The professional organization of pharmaceutical companies operating in France. Leem, Les Entreprises du médicament, brings together companies in the pharmaceutical industry sector in France. Created over 130 years ago, Leem now has nearly 270 member companies, which generate nearly 98% of the total pharmaceutical turnover in France. The pharmaceutical industry employs 100,000 people in over 150 professions, and has recruited 10,000 employees per year for the past 10 years. Each year, the pharmaceutical industry invests 12% of its turnover in research, in order to develop new innovative treatments. It brings together more than 20,000 people in its … Sectors: Startup accelerator & VC | 726 | 387 | 261 | |
Greater Paris University Hospitals - AP-HP Nous soignons et innovons 365 jours par an. AP-HP (Greater Paris University Hospitals) is a European world-renowned university hospital. Its 39 hospitals treat 8 million people every year: in consultation, emergency, during scheduled or home hospitalizations. The AP-HP provides a public health service for everyone, 24 hours a day. This mission is a duty as well as a great source of pride. AP-HP is the leading employer in the Greater Paris area: 100.000 staff members – doctors, researchers, paramedical staff, administrative personnel and workers – work there. Toutes les spécialités médicales de la néonatologie à la gériatrie en passant par … Sectors: Health | 2167 | 1488 | 149 | |
France Biotech Entrepreneurs in HealthTech Created in 1997, the association is the French non-profit organization that brings together the country's leading innovative health compagnies and their expert partners (investors, lawyers, research institutes, cluster, etc...). Its core mission is to promote health innovation in France and help the sector's start-up companies and SMEs to become tomorrow's leaders able to rapidly develop new therapeutic solutions. Our Missions: To support innovative start-ups and SMEs of the HealthTech industry (biotech, medtech, digital health, big data) by tackling four major issues: - Financial: encourage investment in health innovation - Tax: ensure fiscal stability - Administrative and regulatory: … Sectors: Biotechnology Startup accelerator & VC | 847 | 500 | 511 | |
Pfizer We’re celebrating 175 years of daring scientific innovation—and we’re not done yet. Every day, we’re channeling our passion and resources into delivering innovative therapies that change the face of healthcare. Let’s outdo yesterday. Follow our progress as we accelerate the next generation of cancer treatments at LetsOutdoCancer.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe and effective and affordable medicines and health care services to the people who need them. Sectors: Pharmaceutical | 1380 | 1073 | 137 | |
Novartis Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand, and Gene and cell therapy Sectors: Pharmaceutical | 1775 | 1581 | 123 | |
Illumina Unlocking the Power of the Genome At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of … Sectors: Biotechnology | 207 | 131 | 42 | |
Alexion Pharmaceuticals, Inc. Transforming Lives, Every Day. Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca. For more than 30 years, Alexion’s mission has been to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, supportive technologies, and healthcare services. Dedicated to continuing its mission as part of AstraZeneca, Alexion recognizes that patients and caregivers are people first, and by understanding their experiences, Alexion is better able to serve their unique needs. Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex … Sectors: Biotechnology Pharmaceutical | 266 | 190 | 35 | |
Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. With approximately 7,000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Baar, Switzerland and we … Sectors: Biotechnology | 700 | 485 | 49 |